Pharmacyte Biotech Stock Market Value
| PMCB Stock | USD 0.68 0.02 3.03% |
| Symbol | PharmaCyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. Anticipated expansion of PharmaCyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive PharmaCyte Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding PharmaCyte Biotech requires distinguishing between market price and book value, where the latter reflects PharmaCyte's accounting equity. The concept of intrinsic value - what PharmaCyte Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push PharmaCyte Biotech's price substantially above or below its fundamental value.
It's important to distinguish between PharmaCyte Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PharmaCyte Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, PharmaCyte Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
PharmaCyte Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PharmaCyte Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PharmaCyte Biotech.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in PharmaCyte Biotech on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding PharmaCyte Biotech or generate 0.0% return on investment in PharmaCyte Biotech over 90 days. PharmaCyte Biotech is related to or competes with Quoin Pharmaceuticals, NovaBay Pharmaceuticals, Alaunos Therapeutics, VivoSim Labs, Impact BioMedical, Pasithea Therapeutics, and Polyrizon. PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for canc... More
PharmaCyte Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PharmaCyte Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PharmaCyte Biotech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.79 |
PharmaCyte Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PharmaCyte Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PharmaCyte Biotech's standard deviation. In reality, there are many statistical measures that can use PharmaCyte Biotech historical prices to predict the future PharmaCyte Biotech's volatility.| Risk Adjusted Performance | 0.0084 | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.01) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PharmaCyte Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PharmaCyte Biotech February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0084 | |||
| Market Risk Adjusted Performance | 0.0031 | |||
| Mean Deviation | 5.18 | |||
| Coefficient Of Variation | (104,498) | |||
| Standard Deviation | 9.63 | |||
| Variance | 92.83 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 7.79 | |||
| Skewness | 3.73 | |||
| Kurtosis | 18.83 |
PharmaCyte Biotech Backtested Returns
PharmaCyte Biotech appears to be out of control, given 3 months investment horizon. PharmaCyte Biotech maintains Sharpe Ratio (i.e., Efficiency) of 0.0286, which implies the firm had a 0.0286 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for PharmaCyte Biotech, which you can use to evaluate the volatility of the company. Please evaluate PharmaCyte Biotech's Risk Adjusted Performance of 0.0084, coefficient of variation of (104,498), and Variance of 92.83 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, PharmaCyte Biotech holds a performance score of 2. The company holds a Beta of 2.78, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PharmaCyte Biotech will likely underperform. Please check PharmaCyte Biotech's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to make a quick decision on whether PharmaCyte Biotech's historical price patterns will revert.
Auto-correlation | 0.46 |
Average predictability
PharmaCyte Biotech has average predictability. Overlapping area represents the amount of predictability between PharmaCyte Biotech time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PharmaCyte Biotech price movement. The serial correlation of 0.46 indicates that about 46.0% of current PharmaCyte Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.46 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out PharmaCyte Biotech Correlation, PharmaCyte Biotech Volatility and PharmaCyte Biotech Performance module to complement your research on PharmaCyte Biotech. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.